A Look at PTC Therapeutics’s Valuation Following FDA Approval of Sephience and Expanded Patient Access Services

If you follow biotech stocks, the recent buzz around PTC Therapeutics (PTCT) might already be on your radar. The excitement centers on the FDA’s long-awaited approval of Sephience, a new therapy aimed at treating phenylketonuria, or PKU. On top of this, PTC quickly partnered with RareMed Solutions to roll out expanded non-commercial pharmacy dispensing and support services. These efforts are designed to make access easier and provide real-world assistance to patients with complex needs. This combination of regulatory success and operational rollout is exactly the kind of event that forces investors to reconsider what the company’s next act might be. It is no surprise the market has reacted. Over the past month alone, PTCT shares jumped 29%, adding to their impressive 85% gain over the past year. While this latest rally follows periods of more tempered growth, the news marks a real shift in momentum for PTC. If you look back, the company has faced pressure from declining revenue and profitability, but the launch of Sephience could reshape the narrative, at least in the short term. After such a run, is PTCT still trading at a discount to its future opportunity, or have yesterday’s headlines already been fully priced in?

Most Popular Narrative: 12.4% Undervalued

The prevailing narrative among analysts is that PTC Therapeutics is currently undervalued by over 12 percent, factoring in a discount rate of 7.59 percent. This perspective comes from a blend of bullish and bearish outlooks, but the consensus points to room for upside based on growth prospects and recent regulatory wins.

The company's ongoing launch strategy for Sephience includes early patient and payer engagement, swift access programs, and leveraging established commercial infrastructure across multiple developed and emerging markets (U.S., EU, Japan, Brazil, LATAM). All of this is occurring within a period of expanding reimbursement and growing healthcare coverage for high-impact rare disease treatments, enabling accelerated topline growth and sustained operating leverage.

Curious what’s fueling this narrative’s bullish stance? A handful of forward-looking assumptions and bold margin forecasts underpin the current fair value. This analysis leans heavily on growth catalysts and a future earnings multiple that surprises even seasoned biotech investors. Want to see what number-crunching makes analysts so confident? The calculation behind this valuation might just change your view on PTCT’s next move.

Result: Fair Value of $66.69 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, significant risks remain, including heavy reliance on a few products as well as unpredictable international revenues, which could quickly change the market's outlook.

Find out about the key risks to this PTC Therapeutics narrative.

Another View: What Does Our DCF Model Say?

While analysts rely on future earnings multiples for their fair value, the SWS DCF model takes a different approach and suggests PTC Therapeutics may be even more undervalued than it appears. Could the cash flow perspective reveal an overlooked opportunity?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out PTC Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own PTC Therapeutics Narrative

If you think the story could play out differently or want to dig into the data yourself, it only takes a few minutes to create your own perspective. Do it your way.

A great starting point for your PTC Therapeutics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.

Looking for more investment ideas?

Smart investors never limit their options. Get ahead of the curve with fresh opportunities. These handpicked themes could connect you to the next breakthrough stock before the crowd.

• Target steady income streams by checking out opportunities in dividend stocks with yields > 3% for stocks offering yields above 3 percent.
• Capture potential in emerging technologies by digging into quantum computing stocks focused on quantum computing breakthroughs.
• Catch rising stars in healthcare tech by investigating healthcare AI stocks shaping the future of medicine and patient care.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com